Janney Montgomery Scott LLC Has $13.89 Million Position in Kenvue Inc. $KVUE

Janney Montgomery Scott LLC boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 14.5% in the first quarter, Holdings Channel reports. The institutional investor owned 805,630 shares of the company’s stock after buying an additional 101,733 shares during the period. Janney Montgomery Scott LLC’s holdings in Kenvue were worth $13,889,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Oak Thistle LLC bought a new position in Kenvue during the 4th quarter worth $1,563,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Kenvue by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 410,874 shares of the company’s stock valued at $7,088,000 after buying an additional 84,219 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Kenvue by 3,889.9% in the 4th quarter. SG Americas Securities LLC now owns 3,075,723 shares of the company’s stock valued at $53,056,000 after buying an additional 2,998,635 shares during the last quarter. Moors & Cabot Inc. increased its stake in shares of Kenvue by 66.9% in the third quarter. Moors & Cabot Inc. now owns 313,122 shares of the company’s stock valued at $5,082,000 after buying an additional 125,517 shares during the period. Finally, Cohen Capital Management Inc. acquired a new stake in shares of Kenvue in the fourth quarter valued at about $2,448,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 1.1%

Shares of NYSE:KVUE opened at $19.33 on Thursday. The business’s 50 day simple moving average is $17.76 and its two-hundred day simple moving average is $17.68. The firm has a market cap of $37.11 billion, a P/E ratio of 22.74, a PEG ratio of 1.45 and a beta of 0.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a 52-week low of $14.02 and a 52-week high of $22.87.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm had revenue of $3.91 billion during the quarter, compared to analysts’ expectations of $3.84 billion. During the same quarter last year, the firm posted $0.24 earnings per share. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, research analysts forecast that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date was Wednesday, May 13th. Kenvue’s payout ratio is 97.65%.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 1.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on KVUE shares. UBS Group lowered their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Argus upgraded Kenvue to a “hold” rating in a report on Friday, March 6th. Citigroup decreased their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, April 15th. Barclays lowered their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Finally, Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.